GlassScriptPhysician profile
Mary C Kirk
NPI 1992819387
$698.90
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $65.54 · 2021: $88.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $228.62 | 2019-2020 | |
| Abbvie INC. | $176.08 | 2019-2021 | |
| Caldera Medical, INC | $73.25 | 2021 | |
| Pfizer INC. | $44.81 | 2019 | |
| Therapeuticsmd, INC. | $40.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.64 | 2019 | |
| Allergan, INC. | $23.40 | 2019 | |
| Duchesnay USA Incorporated | $17.90 | 2019 | |
| Avion Pharmaceuticals | $14.98 | 2019 | |
| Lilly USA, LLC | $13.69 | 2020 | |
| Acessa Health INC. | $13.38 | 2019 | |
| Exeltis, USA INC. | $11.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.